Salem Investment Counselors Inc Bristol Myers Squibb CO Transaction History

Salem Investment Counselors Inc

$2.99 Billion
Q4 2024

A detailed history of Salem Investment Counselors Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Salem Investment Counselors Inc holds 31,208 shares of BMY stock, worth $1.92 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

31,208

Previous 32,313 3.42%

Holding current value

$1.92 Million

Previous $1.67 Million 5.56%

% of portfolio

0.06%

Previous 0.05%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 13, 2025	SELL	$51.92 - $59.94 $57,371 - $66,233	-1,105 Reduced 3.42%	31,208 $1.77 Million
Q3 2024 Oct 15, 2024	SELL	$39.66 - $51.75 $126,951 - $165,651	-3,201 Reduced 9.01%	32,313 $1.67 Million
Q2 2024 Jul 11, 2024	SELL	$40.25 - $52.99 $1.64 Million - $2.16 Million	-40,854 Reduced 53.5%	35,514 $1.47 Million
Q1 2024 Apr 11, 2024	SELL	$47.98 - $54.4 $299,635 - $339,728	-6,245 Reduced 7.56%	76,368 $4.14 Million
Q4 2023 Jan 16, 2024	SELL	$48.48 - $57.85 $974,690 - $1.16 Million	-20,105 Reduced 19.57%	82,613 $4.24 Million
Q3 2023 Oct 04, 2023	SELL	$57.89 - $64.73 $129,036 - $144,283	-2,229 Reduced 2.12%	102,718 $5.96 Million
Q2 2023 Jul 19, 2023	SELL	$63.71 - $70.74 $258,089 - $286,567	-4,051 Reduced 3.72%	104,947 $6.71 Million
Q1 2023 May 11, 2023	BUY	$65.71 - $74.53 $704,016 - $798,514	10,714 Added 10.9%	108,998 $7.55 Million
Q4 2022 Feb 15, 2023	BUY	$68.48 - $81.09 $608,650 - $720,727	8,888 Added 9.94%	98,284 $7.07 Million
Q3 2022 Nov 09, 2022	SELL	$0.13 - $76.84 $0 - $307	-4 Reduced -0.0%	89,396 $6.36 Million
Q2 2022 Aug 17, 2022	BUY	$72.62 - $79.98 $304,132 - $334,956	4,188 Added 4.91%	89,400 $6.93 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $823,524 - $987,479	-13,395 Reduced 13.58%	85,212 $6.22 Million
Q4 2021 Feb 15, 2022	BUY	$53.63 - $62.52 $155,687 - $181,495	2,903 Added 3.03%	98,607 $6.15 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $188,101 - $220,336	3,179 Added 3.44%	95,704 $5.66 Million
Q2 2021 Aug 17, 2021	BUY	$61.91 - $67.42 $1.78 Million - $1.94 Million	28,736 Added 45.05%	92,525 $6.18 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $460,359 - $517,768	7,758 Added 13.85%	63,789 $4.03 Million
Q4 2020 Feb 17, 2021	BUY	$57.74 - $65.43 $5,254 - $5,954	91 Added 0.16%	56,031 $3.48 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $456,855 - $506,256	7,955 Added 16.58%	55,940 $3.37 Million
Q2 2020 Aug 13, 2020	BUY	$54.82 - $64.09 $225,310 - $263,409	4,110 Added 9.37%	47,985 $2.82 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $604,870 - $879,017	13,036 Added 42.27%	43,875 $2.45 Million
Q4 2019 Feb 13, 2020	SELL	$49.21 - $64.19 $42,714 - $55,716	-868 Reduced 2.74%	30,839 $1.98 Million
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $1.25 Million - $1.48 Million	-29,169 Reduced 47.92%	31,707 $1.61 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $1.15 Million - $1.27 Million	-25,671 Reduced 29.66%	60,876 $2.76 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $202,272 - $241,185	4,483 Added 5.46%	86,547 $5.37 Million
Q4 2018 Feb 15, 2019	SELL	$48.76 - $63.23 $218,591 - $283,460	-4,483 Reduced 5.18%	82,064 $4.27 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $85,986 - $96,985	-1,558 Reduced 1.77%	86,547 $5.37 Million
Q2 2018 Aug 15, 2018	SELL	$50.53 - $62.98 $692,463 - $863,077	-13,704 Reduced 13.46%	88,105 $4.88 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $162,263 - $186,797	-2,708 Reduced 2.59%	101,809 $6.28 Million
Q4 2017 Feb 16, 2018	BUY	$59.94 - $65.35 $120,299 - $131,157	2,007 Added 1.96%	104,517 $6.41 Million
Q3 2017 Nov 16, 2017	BUY	$55.23 - $63.74 $5.66 Million - $6.53 Million	102,510	102,510 $6.63 Million

Others Institutions Holding BMY

# of Institutions

2,762

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $131B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Salem Investment Counselors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Salem Investment Counselors Inc with notifications on news.

Account

Salem Investment Counselors Inc Bristol Myers Squibb CO Transaction History